Amgen and AstraZeneca have said their severe asthma therapy Tezspire could have a role to play in chronic obstructive pulmonary disease (COPD) – a key target indication fo
Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced las
The Institute for Clinical and Economic Review (ICER) typically focuses on the cost-effectiveness of new therapies, but in an unusual move has sharply criticised the desig
New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myer
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.